Cytokine gene expression during the generation of human lymphokine-activated killer cells: early induction of interleukin 1 beta by interleukin 2.
Culture of human peripheral blood leukocytes with interleukin 2 (IL-2) stimulates their differentiation into lymphokine-activated killer (LAK) cells, with a broad range of cytotoxicity against fresh tumor cells and tumor cell lines (Grimm et al., J. Exp. Med., 155: 1823-1841, 1982). We chose to utilize a molecular approach to determine whether IL-2 stimulates the expression of cytokine genes by the mixed cell population which may be involved in the generation or regulation of lytic activity. Northern blot analysis performed with total cellular RNA from LAK cells cultured for varying periods of time with IL-2 revealed that the genes which code for cytokines [interleukin 1 (IL-1)alpha and beta, gamma-interferon, tumor necrosis factor alpha, and lymphotoxin] were not spontaneously expressed. As soon as 2 h after IL-2 treatment, IL-1 alpha and IL-1 beta mRNAs were expressed. Both nonadherent and adherent populations of LAK cells express IL-1 beta mRNA; however, the adherent population produced more IL-1 beta mRNA and maintained its expression for a prolonged period of time. Other cytokine mRNAs (gamma-interferon, tumor necrosis factor alpha, and lymphotoxin) were expressed later than the IL-1 mRNAs with maximal levels between Days 2 through 7. Our results indicate that LAK cell populations can generate a variety of cytokines which may be involved in the generation of lytic activity.
Kovacs
E J
EJ
Department of Anatomy, Loyola University, Maywood, Illinois.
Beckner
S K
SK
Longo
D L
DL
Varesio
L
L
Young
H A
HA
D002469:Cell Separation; D005796:Genes / Q000187:drug effects; D006801:Humans; D007375:Interleukin-1 / Q000235:genetics*; D007376:Interleukin-2 / Q000502:physiology / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D007700:Kinetics; D008213:Lymphocyte Activation; D009000:Monocytes / Q000166:cytology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D012333:RNA, Messenger / Q000235:genetics; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000166:cytology; D014158:Transcription, Genetic / Q000187:drug effects
D007375:Interleukin-1; D007376:Interleukin-2; D012333:RNA, Messenger; D011994:Recombinant Proteins